Advertisement

Topics

Genentech’s Emicizumab Receives Priority Review from the FDA for Treatment of Hemophilia A with Inhibitors

14:13 EDT 24 Aug 2017 | Speciality Pharma Journal

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis (preventative) as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A …

Original Article: Genentech’s Emicizumab Receives Priority Review from the FDA for Treatment of Hemophilia A with Inhibitors

NEXT ARTICLE

More From BioPortfolio on "Genentech’s Emicizumab Receives Priority Review from the FDA for Treatment of Hemophilia A with Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...